XCENA
Builds CXL computational memory chips and SDK for AI infrastructure in hyperscalers, telcos, and research
$135MSeries B
Role not disclosedLI
LB Investment
Activity from announced rounds
Activity in this selectionMay 31, 2026 · May 1, 2026
LB Investment is the Korean investment firm identified as lead by ImpriMed and associated with partner Kiho Park.
Recorded funding activity
ImpriMed tests live cancer cells against medicines and combines the results with clinical data. Point2 develops interconnect hardware, while CarbonSix develops robotic intelligence for manufacturing. These companies retain their distinct products and participant roles.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $135M 1 disclosed · full round size, not this investor’s share